WO2006024240A2 - Composición vacunal contra el virus de la hepatitis c. - Google Patents
Composición vacunal contra el virus de la hepatitis c. Download PDFInfo
- Publication number
- WO2006024240A2 WO2006024240A2 PCT/CU2005/000005 CU2005000005W WO2006024240A2 WO 2006024240 A2 WO2006024240 A2 WO 2006024240A2 CU 2005000005 W CU2005000005 W CU 2005000005W WO 2006024240 A2 WO2006024240 A2 WO 2006024240A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antigens
- hcv
- response
- vaccine composition
- virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- the present invention is related to the branch of immunology, particularly with a composition of vaccine antigens that are capable of inducing an enhanced and diverse immune response against Hepatitis C virus (HCV) and combined vaccines against pathogenic entities including this vaccine composition .
- HCV Hepatitis C virus
- State of the prior art There are several obstacles to obtaining an effective vaccine against HCV since being an RNA virus, it can quickly mutate in adaptation to the environment. This contributes to the high sequence diversity of the multiple viral isolates identified in the world. The greatest heterogeneity is concentrated in the hypervariable region of HCV E2 protein, where there is precisely a possible neutralizing epitope (Bukh et al. US 6,110,465).
- HCV causes persistent infection in immunocompetent individuals despite the existence of an active immune response (Lechmann et al. (2000) Vaccine development for hepatitis C. Semin Liver Dis. 20: 211-226).
- an active immune response Lechmann et al. (2000) Vaccine development for hepatitis C. Semin Liver Dis. 20: 211-226.
- an animal model nor an efficient in vitro culture system that allows the virus to spread and evaluate the existence of neutralizing antibodies.
- the immunological patterns associated with the progression of the disease or with the protection have not been defined. It is likely that a vigorous multispecific response, both humoral and long-lasting, will be required for the resolution of the infection (Lechmann et al. (2000) Vaccine development for hepatitis C. Semin Liver Dis. 20: 211-226).
- Vaccination improved liver histology determined the disappearance of viral antigens from the liver and decreased alanine aminotransferase (ALT) levels.
- serum viral RNA levels did not change during treatment, liver inflammation and viral antigens reappeared after the end of treatment.
- An association was observed between the high levels of antibodies against E1 and the improvement of the disease (Maertens et al. (2000) Improvement of chronic active hepatitis C chronically infected chimpanzees after therapeutic vaccination with the HCV E1 protein. Acta Gastroenterol. BeIg 63: 203).
- virus-like particles Liang et al.
- peptides without helper function can be poor immunogens;
- effectiveness of a vaccine is often based on the induction of a multivalent broad-spectrum response against different antigens.
- HCV envelope proteins have also been targets of interest for this type of technology.
- E2 the humoral response appears to be directed primarily at RHV-1 (Lee et al. (1998) Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses. Mol. CeIIs 8: 444- 451).
- RHV-1 Hepatitis C virus envelope DNA-based immunization elicits humoral and cellular immune responses.
- Mol. CeIIs 8: 444- 451 When it has been immunized with vectors coding for secretable variants of the E1 and E2 proteins, no differences in the immune response have been obtained when compared with the secreted variants (Lee et al.
- Non-structural proteins have also been evaluated by this technology.
- the coding region for the C-terminal domain of the NS3 protein was included in a vector that allows simultaneous and independent expression of said domain and IL-2, obtaining good results (Papa et al. (1998) Development of multigenetic plasmid vector for HCV DNA immunization Res. Virol. 149: 315-319).
- the NS4 and NS5 proteins also generate cytotoxic and Acs T lymphocyte responses in this way (Encke et al. (1998) Genetic immunization generates cellular and humoral Immune responses against the nonstructural proteins of the hepatitis C virus in murine model. J. Immunol. 161: 4917-4923).
- the vaccine composition composed of the complex formed by the surface antigen, an antibody against this antigen, and a plasmid coding for this antigen has been evaluated (Wen et al. US 6,221, 664) .
- This formulation allowed the antigen presentation by several pathways and a rapid induction of immune response that was superior to that generated by the individual variants.
- the present invention describes a vaccine composition composed of the structural antigens of the Hepatitis C virus. Unlike the protein compositions described above where only the combined E1 and E2 proteins were used or alone, our protein also includes the protein of the virus capsid.
- composition lies in the ranges of amounts of antigen to be used in the preparation which allows, in addition, to generate potent responses (humoral and cellular) against different antigens simultaneously and a protective response to the challenge in murine model with vaccinia virus recombinant
- the present invention aims at providing a vaccine composition composed of the mixture of the structural antigens of the Hepatitis C virus.
- the protein of the capsid, the structural protein E1 and the structural protein E2 are capable of inducing specific humoral and cellular immunity against HCV, even (but not only) in chronic HCV carriers.
- the novelty of the invention is given by obtaining a range of antigen ratios and the protective effect that is obtained after the immunization of the mixtures under study.
- the antigens under study are attractive vaccine targets through which an immune response against HCV can be generated.
- the vaccine composition uses a range of ratios of the antigens present that is framed between [(1, 5-2.5) :( 1-2.5) :( 1-2)] for the protein of The capsid, E1 and E2 respectively, to generate an optimal humoral response.
- the protein antigens are used in a ratio of (1, 5: 1,1: 1) for the Protein of the capsid, E1 and E2 respectively.
- the vaccine composition uses a range of ratios of the antigens present which is framed between [(1:50) :( 120-180) :( 120-180)] for the protein of the capsid, E1 and E2 respectively, to generate a optimal cellular response
- the protein antigens are used in a ratio of (1: 160: 160) for the protein of the capsid, E1 and E2 respectively.
- the vaccine composition of the present invention can be administered as a solid, liquid or aerosol product, by any convenient method for the administration of vaccines including oral and parenteral injection (eg intravenous, subcutaneous or intramuscular), in addition this composition can be prepared by mixing the protein antigens and then adding them, or by adding the antigens separately and then mixing them.
- the antigens according to this invention may be prepared naturally or by recombinant DNA techniques in any expression system as documented below.
- the vaccine compositions comprising this invention can be administered in different immunization schedules.
- the vaccine compositions comprise combinations of the antigens of the structural region of the Hepatitis C Virus, together with plasmids that code for antigens of infectious entities against viral and / or bacterial diseases.
- the preferred vaccine compositions in this invention are preparations where the viral antigens used are the nucleocapsid antigen and / or the surface antigen of the Hepatits B virus and as bacterial antigens the outer membrane proteins of N. meningitidis as prepared vaccine or any of the proteins that make up the same, likewise, polysaccharide antigens conjugated or not to carrier proteins can be used as active principles of formulations against bacterial entities.
- the vaccine compositions described herein can be administered in combination schemes with other vaccine candidates based on DNA vaccines, recombinant live vectors, peptides and proteins. They can also be used to induce immunity against HCV in patients with chronic hepatitis C, cirrhosis and liver cancer.
- FIG. 1 Antibody response against the HCV structural proteins evaluated by ELISA, (A) against the HCV capsid antigen, (B) against the E1 protein, (C) against the E2 protein.
- Figure 2 Lymphoproliferative response against the proteins of the structural region of HCV, from splenocytes of mice immunized with the combinations under study.
- HCcAg, HCV capsid antigen, E2-coli, E2 produced in
- Figure 3 Functional response of the preparations under study evaluated against the challenge with recombinant vaccinia virus.
- Figure 4 Analysis of the influence on (A) Antibody response, (B)
- Lymphoproliferative response (C) Challenge with recombinant vaccinia virus, of the components present in the vaccine preparation.
- Figure: 5 Evaluation of the influence of the range of relationships to be used in the vaccine vaccine preparation against HCV, for antibody response (A) against the HCV capsid antigen, (B) against protein E1, (C) against The protein
- Figure: 6 Evaluation of the influence of the range of relationships to be used in the vaccine preparation on the lymphoproliferative response against the proteins of the structural region of HCV, from splenocytes of immunized mice.
- HCcAg HCV capsid antigen
- E2-coli E2 produced in Escherichia coli
- E2-lev E2 produced in the yeast Pichia pastoris, E1-coli, E1 produced in
- Figure: 7 Influence of the range of relationships to be used in the vaccine preparation on the functional response evaluated against the challenge with recombinant vaccinia virus in immunized mice.
- Figure: 8 Antibody response against HCV structural proteins evaluated by ELISA, (A) against HCV capsid antigen, (B) against Ia protein E1, (C) against protein E2, after immunization at different time intervals (different immunization schedules).
- Figure: 9 Lymphoproliferative response against proteins in the structural region of HCV, from splenocytes of mice immunized with different schemes. HCcAg, HCV capsid antigen, E2-coli, E2 produced in
- Figure: 10 Functional response to the challenge with recombinant vaccinia virus after
- Figure: 11 Antibody response against the HCV structural proteins evaluated by ELISA, (A) against the HCV capsid antigen, (B) against the E1 protein, (C) against Ia E2 protein, after immunization with the vaccine against HCV by different routes.
- Figure: 12 Lymphoproliferative response against proteins of the HCV structural region, from splenocytes of mice immunized with HCV protein vaccine preparations, supplied by different routes.
- HCcAg HCV capsid antigen, E2-coli, E2 produced in Escherichia coli, E2-lev,
- Figure: 14 Antibody response against the HCV structural proteins evaluated by ELISA, (A) against the HCV capsid antigen, (B) against the EI 1 (C) protein against the E2 protein, to analyze the influence of different adjuvants in the humoral response.
- Figure: 15 Lymphoproliferative response against the proteins of the structural region of HCV, from splenocytes of mice immunized for the evaluation of different adjuvants.
- HCcAg HCV capsid antigen, E2-coli, E2 produced in Escherichia coli, E2-lev, E2 produced in Pichia pastor ⁇ s yeast,
- E1-coli E1 produced in Escherichia coli.
- Figure: 16 Functional response to the challenge with recombinant vaccinia virus after immunization of mice for the study of different adjuvants.
- Figure: 17 Antibody response, (A) against the HCV capsid antigen, (B) against E1 protein, (C) against E2 protein, against (D) HBsAg and (E) HBcAg evaluated by ELISA, after immunization with The mixture of the vaccine preparation against HCV and viral antigens.
- Figure: 18 Lymphoproliferative response against the proteins of the structural region of HCV (capsid protein, E1, E2), HBsAg and HBcAg, from splenocytes of mice immunized with combinations of the vaccine preparation against HCV and viral antigens.
- HCV capsid antigen E2-coli, E2 produced in Escherichia coli, E2-lev, E2 produced in the yeast Pichia pastoris, E1-coli, E1 produced in Escherichia coli.
- Figure: 19 Functional response to the challenge with recombinant vaccinia virus after immunization of mice with a combination of the vaccine against HCV and viral antigens.
- Figure: 20 Antibody response, (A) against the HCV capsid antigen, (B) against E1 protein, (C) against E2 protein and (D) against proteins of the outer membrane of N. meningitidis, evaluated by ELISA, after immunization with the mixture of the vaccine preparation against HCV and bacterial antigens (proteins of the outer membrane of Neisseria meningitidis).
- Figure: 21 Lymphoproliferative response against proteins of the HCV structural region (capsid protein, E1, E2) and proteins of the outer membrane of N.
- HCV bacterial antigens
- PME proteins of the outer membrane of Neisseria meningitidis
- HCcAg HCV capsid antigen
- E2-coli E2 produced in Escherichia coli
- E2-lev E2 produced in the yeast Pichia pastoris
- E1-coli E1 produced in Escherichia coli.
- Figure: 22 Functional response to the challenge with recombinant vaccinia virus after immunization of mice with a combination of the vaccine preparation against HCV and bacterial antigens (proteins of the outer membrane of Neisseria meningitidis).
- Figure: 23 Antibody response, (A) against the HCV capsid antigen, (B) against E1 protein, (C) against E2 protein and (D) against capsular polysaccharide of serogroup C of N. meningitidis , evaluated by ELISA, after mixing the vaccine preparation against HCV and a conjugated capsular polysaccharide.
- Figure: 24 Lymphoproliferative response against HCV structural region proteins (capsid protein, E1, E2) from splenocytes of mice immunized with the mixture of the vaccine against HCV and a conjugated capsular polysaccharide.
- HCcAg HCV capsid antigen, E2-coli, E2 produced in Escher ⁇ chia coli, E2-lev, E2 produced in Pichia pastoris yeast, E1-coli, E1 produced in Escher ⁇ chia coli.
- Figure: 25 Functional response to the challenge with recombinant vaccinia virus after immunization of mice with the mixture of the vaccine against HCV and a conjugated capsular polysaccharide.
- Figure: 26 Antibody response, (A) against the HCV capsid antigen, (B) against E1 protein, (C) against E2 protein, (D) against HBsAg, and (E) against HBcAg, after The mixture of the vaccine preparation against HCV and plasmids coding for HBsAg and HBcAg.
- Figure: 27 Lymphoproliferative response against the proteins of the structural region of HCV (capsid protein, E1, E2), HBsAg and HBcAg, from splenocytes of mice immunized with combinations of the vaccine preparation against HCV and plasmids encoding HBsAg and HBcAg.
- HCcAg HCV capsid antigen, E2-coli, E2 produced in Escher ⁇ chia coli, E2-lev, E2 produced in Pichia pastoris yeast, E1-coli, E1 produced in Escher ⁇ chia coli.
- Figure: 28 Functional response to the challenge with recombinant vaccinia virus after immunization of mice with a combination of the vaccine against HCV and plasmids encoding HBsAg and HBcAg.
- FIG. 29 Antibody response, (A) against the HCV capsid antigen, (B) against E1 protein, (C) against E2 protein, after immunization of mice with combinations of DNA and booster dose with preparation HCV protein.
- Figure: 30 Lymphoproliferative response against proteins in the structure region! HCV (capsid protein, E1, E2), from splenocytes of mice immunized with combinations of DNA and booster doses with HCV protein preparation.
- HCV capsid protein
- HCcAg HCV 1 capsule antigen E2-coli, E2 produced in Escher ⁇ chia coli, E2-lev, E2 produced in the yeast Pichia pastoris, E1-coli, E1 produced in Escher ⁇ chia coli.
- Figure: 31 Functional response to the challenge with recombinant vaccinia virus after immunization of mice with combinations of DNA and booster doses with HCV protein preparation.
- Figure: 32 Antibody response against HCV structural proteins (capsid protein, E1, E2), after the immunization of mice with different ways of shaping the vaccine preparation.
- Figure: 33 Iinfoproliferative response against the proteins of the structural region of HCV (capsid protein, E1, E2), from splenocytes of mice immunized with different ways of forming the vaccine preparation against HCV.
- HCV capsid antigen E2-coIi
- E2 produced in Escherichia coli
- E2-lev E2 produced in Pichia pastoris yeast
- E1-coli E1 produced in Escherichia coli.
- Figure: 34 Functional response to the challenge with recombinant vaccinia virus after immunization of mice with different ways of shaping the vaccine preparation.
- Example 1 Antibody response, inflammatory and challenge against recombinant vaccinia virus in mice immunized with HCV protein vaccine preparation.
- the antigens of the capsid, E1 and E2 of HCV, after being mixed and adjuvant in alumina were inoculated intraperitoneally to female BALB / c mice (10 per group).
- the scheme included 3 inoculations on days 0, 7, 14.
- the study of the humoral and cellular response (lymphoproliferative response), as well as protection against challenge against recombinant vaccinia virus vRE (which contains the proteins of the structural region of HCV) was performed 15 days after the last immunization.
- the relationship of the groups under study is shown in Table 1.
- Table 1 Preparation of the immunogens to be used in the assay.
- the antibody response was determined by an immuno-enzymatic assay (ELISA) against the proteins of the HCV structural region.
- ELISA immuno-enzymatic assay
- the multiple range variance analysis and the Kruskal-Wallis post-test was used to statistically analyze the results, p ⁇ 0.05 was considered a statistically significant difference.
- Figure 1 shows that it is possible to obtain an antibody response against the three antigens of the HCV structural region when they are administered in certain ratios.
- mice were immunized ip, in the same regime described in example 1, with the proportions of the capsid antigens , E1 and E2 of HCV as shown in Table 2.
- the amounts used for each antigen were the result of the analysis of the response surface graphs of example 1.
- the antibody response against the HCV structural proteins is shown in Figure 5 indicating that the relationships under study generate an antibody response against the capsid antigen, E1 and E2 of HCV. Despite the variations in the antibody response observed for each antigen, no statistically significant difference was found between them for each of the variants (optimal variant of cellular response and optimal variant for the humoral response, respectively).
- the experimental groups represented in Figure 5 correspond to those shown in Table 2.
- the study of the lymphoproliferative response was evaluated by the incorporation of thymidite- 3 H, after stimulation of the spleen cells of immunized mice. Immunized mice showed generating a lymphoproliferative response against the antigens under study, as shown in Figure 6.
- the experimental groups represented in Figure 6 correspond to those shown in Table 2, adding another corresponding negative control (group 17) to non-immunized mice. No statistically significant differences were observed between the stimulation indices obtained for each of the variants under study (optimal variant of cellular response and optimal variant for humoral response, respectively).
- FIG. 7 shows the levels of protection achieved, where the reduction in viral load is significant in mice immunized with protein mixtures in the ranges under study (approximately 2.5 Log of viral titer), mainly in the optimal variant for response mobile.
- the experimental groups represented in Figure 7 correspond to those shown in Table 2, adding another negative control (group 17) corresponding to non-immunized mice.
- Example 3 Evaluation of the immune response in BALB / c mice after immunization with HCV protein preparations provided in different immunization schedules.
- mice Female BALB / c mice were immunized i.p. at different time intervals, with the preparation to generate the optimal cellular response, as referred to in example 1.
- the immunization scheme for group 1 was at weeks 0, 1, 2.
- the immunization scheme for group 2 It was 0, 2, 4 weeks.
- the immunization schedule for group 3 was 0, 3, 6 weeks and for group 4 it was 0, 4, 8 weeks.
- Antibody titers against HCV capsid proteins, E1 and E2 were evaluated by ELISA and are reported in Figure 8. As it is observed there were no statistically significant differences in the titer of immunized mice when they were evaluated 15 days later. of the last immunization against E1 and E2. against the capsid antigen, statistically significant differences were found when the immunization regimens were compared 0, 1, 2 weeks (group 1) and the remaining employees.
- mice Female BALB / c mice were immunized with preparations to generate optimal cellular and humoral responses by route: Group 1: Optimal preparation for humoral response subcutaneously (sc), Group 2: Optimal preparation for humoral response via Lp., Group 3: Optimal preparation for humoral response by intramuscular route (Lm.), Group 4: Optimal preparation for humoral response by intra-nasal route (Ln.), Group 5: Optimal preparation for cellular response by sc route, Group 6: Optimal preparation for cellular response via Lp., Group 7: Optimal preparation for cellular response via Lm., Group 8: Optimal preparation for cellular response via in.
- sc subcutaneously
- Group 3 Optimal preparation for humoral response by intramuscular route (Lm.)
- Group 4 Optimal preparation for humoral response by intra-nasal route (Ln.)
- Group 5 Optimal preparation for cellular response by sc route
- Group 6 Optimal preparation for cellular
- the antibody response was studied 15 days after the completion of the immunization schedule ( 0, 1, 2 weeks) against the 3 antigens that are part of the structural region of HCV (capsid antigen, E1 and E2 of HCV).
- the results obtained show that despite there being differences between the levels of Ac, a specific response was generated against the antigens used. These differences are due to the immunization scheme used, where the generation of antibody response is favored for some immunization variants by the kinetics of generating the immune response. No statistically significant differences were observed between the groups when the sc, ip and im routes were used. However, the results were higher when using the ip route, and lower with statistically significant differences when using the Ln route. The results obtained are shown in Figure 11.
- mice immunized in the scheme was evaluated against viral antigens, 15 days after the end of the scheme. immunization.
- the differences in the stimulation indices between the groups under study are attributed to the amount of antigen used, for the route in, and the kinetics of generation of the immune response in general for all immunization routes
- a specific lymphoproliferative immune response was generated for each antigen, however the stimulation rates for the in pathway were statistically lower compared to the other pathways.
- Figure 12 shows the results obtained.
- Example 5 Evaluation of the immune response in BALB / c mice after immunization with HCV protein preparations using different adjuvants.
- mice were immunized Lp. with preparations to generate the optimal cellular and humoral responses adjuvant with: Group 1: Optimal variant for humoral response adjuvant with aluminum hydroxide (Alumina (AIOH 3 )), group 2: Optimal variant for humoral response adjuvant with aluminum phosphate, group 3: Optimal variant for humoral response adjuvant with Freund's adjuvant, group 4: Optimal variant for humoral response adjuvant with oily adjuvant (Montanide ISA 51), group 5: Optimal variant for humoral response without adjuvant, group 6: Optimal variant for response cell adjuvant with aluminum hydroxide (Alumina (AIOH 3 )), group 7: Optimal variant for cellular response adjuvant with aluminum phosphate, group 8: Optimal variant for cellular response adjuvant with Freund's adjuvant, group 9: Optimal variant
- the antibody response was studied 15 days after the end of the immunization schedule (0, 1, 2 weeks) against the 3 antigens that form the structural region of HCV (capsid antigen, E1 and E2 of HCV). The results obtained show that despite there being differences between the levels of antibodies generated, a specific response was obtained against the antigens used.
- Antibody levels were similar when the variants were adjuvated with both aluminum hydroxide and aluminum phosphate.
- the highest levels of antibodies were obtained by using Freund's adjuvant in vaccine preparations and subsequently to a lesser extent those adjuvants with Montanide ISA-51.
- the lowest levels of antibodies obtained were when no adjuvant was used in vaccine preparations, although a specific antigen response was generated.
- the results obtained are shown in Figure 14.
- the lymphoproliferative response in the spleen cells of the immunized mice was evaluated against the viral antigens of the structural region, 15 days after the completion of the immunization schedule.
- the highest lymphoproliferation rates were obtained for the cell variant adjuvant with Freund and Montanide ISA-51, respectively.
- the lymphoproliferation rates for the variants where both aluminum hydroxide and aluminum phosphate were used were similar.
- the lowest levels of cellular response were obtained when the vaccine preparation was given to the mice in the absence of adjuvant.
- Figure 15 shows the results obtained, also including another negative control group (Group 11), corresponding to non-immunized mice.
- This figure shows a reduction of 1, 7 (optimal variant for humoral response) and 2.4 (optimal variant for cellular response) of the viral titer log in mice immunized with Freund's adjuvant, as well as 1.9 ( optimal variant for humoral response) and 2.5 (optimal variant for cellular response) of the Title Log for those immunized with Montanide ISA-51, respectively.
- both hydroxide and phosphate Ia reduction in the Log of the viral titer in the ovaries of immunized and challenged mice was 1.4 (optimal variant for humoral response) and 2.1 (optimal variant for cellular response) orders of magnitude.
- a small reduction in viral titer was observed in those mice immunized without adjuvant and then challenged with the vRE.
- Example 6 Evaluation of the immune response in BALB / c mice after immunization with HCV protein preparations mixed with other viral antigens.
- the potentiation or generation of the immune response by other viral antigens surface antigen of the Hepatitis B-HBsAg virus, antigen of the capsid of the Hepatitis B-HBcAg virus) mixed with the vaccine preparation against HCV (vaccine preparation that generates optimal cellular response) under study was evaluated after immunization of mice.
- BALB / c mice were immunized i.p. with: group 1- HBsAg-vaccine preparation, group 2- HBcAg-vaccine preparation, group 3-vaccine preparation, group 4- HBsAg, group 5- HBcAg.
- the immunization schedule used was 0, 2, 4 weeks and the immune response studied 15 days after the end of the immunization schedule.
- the antibody response was evaluated against the 3 antigens that form the structural region of HCV (capsid antigen, E1 and E2 of HCV), as well as against HBsAg and HBcAg. A generation of the specific antigen immune response was observed.
- Antibodies against the viral antigens HBsAg and HBcAg were generated. Although the levels of antibodies against HBcAg in group 2 (HBcAg-HCV vaccine preparation) were slightly lower compared to the control (group 5- HBcAg), the differences obtained were not statistically significant.
- the lymphoproliferative response in the spleen cells of the immunized mice was evaluated against viral antigens of the structural region of HCV, as well as against HBsAg and HBcAg, 15 days after the end of the immunization schedule. As shown in Figure 18, there was no variation in the stimulation indices when the vaccine preparation mixed with the viral antigens (HBsAg or HBcAg) and their respective controls was compared. An antigen-specific response was generated in each case. The differences in the stimulation indexes detected were not statistically significant, when the study groups were compared. Another negative control group (Group 6), corresponding to non-immunized mice, was included in the experiment.
- mice The potentiation or generation of the immune response generated by the combination of the vaccine preparation with bacterial antigens (outer membrane proteins (PME) of Neisseria meningitidis) mixed with the vaccine preparation (vaccine preparation that generates optimal cellular response) under study was evaluated after immunization of mice.
- BALB / c mice were immunized ip with: group 1- PME-HCV vaccine preparation, group 2- HCV vaccine preparation, group 3- PME adjuvated with aluminum hydroxide.
- the immunization scheme used was 0, 2, 4 weeks and the immune response was studied 15 days after the end of the immunization scheme.
- the antibody response was evaluated against the 3 antigens that make up the structural region of HCV (capsid antigen, E1 and E2 of HCV), as well as against a protein preparation of the outer membrane of N. meningitidis corresponding to the Cuban strain CU 385/83.
- Figure 20 shows that the levels of antibodies generated by the combination of the vaccine preparation with the PME generated higher levels of antibodies when these were compared both against those generated by the group of mice immunized with PME as well as with the HCV preparation related to the independent antigens as to PME. These differences had no statistical significance.
- the lymphoproliferative response in the spleen cells of the immunized mice was evaluated against the viral antigens of the structural region of the HCV, as well as against the PME of the Cuban strain CU385 of N. meningitidis, 15 days after the end of the immunization schedule.
- FIG 21 there was an increase in the stimulation indexes when the spleen cells of the mice immunized with the combination PME-HCV vaccine preparation were stimulated with the antigens of the structural region of the HCV as well as with the PME, in comparison to the control groups. This stimulation was specific antigen.
- the functional activity of the antibodies generated with respect to the bacterial entity from which the PMEs were purified was evaluated by the bactericidal assay. In this test the property of the antibodies to kill the bacterium in vitro in the presence of exogenous complement is measured. In this sense, the results shown in Table 3, indicate that the mixture of vaccine preparation against HCV with PME, did not inhibit or potentiate the generation of specific-functional antibodies against N. meningitidis, since the bactericidal titres of groups 1 and 3 were similar.
- Bactericidal titres are expressed as Log 2 of the last dilution of the serum capable of killing 50% of the initial inoculum of bacteria used in the assay.
- Example 8 Evaluation of the immune response in BALB / c mice after immunization with HCV protein preparations mixed with polysaccharides.
- capsular polysaccharides capsule polysaccharide of Neisseria meningitidis serogroup C-conjugated with a P64k carrier protein
- vaccine preparation that generates optimal cellular response
- group 1- Conjugate MenC-P64k
- group 2- vaccine preparation against HCV group 3- Conjugate
- MenC-P64k group 1- Conjugate
- the immunization scheme used was 0, 2, 4 weeks and the immune response was studied 15 days after the end of the immunization scheme.
- the antibody response was evaluated against the 3 antigens that make up the structural region of HCV (capsid antigen, E1 and E2 of HCV), as well as against the capsular polysaccharide of N. meningitidis serogroup C.
- Figure 23 shows that the levels of antibodies generated by the combination of the vaccine preparation with the conjugate were similar when they were evaluated both against the HCV structural proteins, as well as against the capsular polysaccharide of serogroup C of N. meningitidis.
- the lymphoproliferative response in the spleen cells of the immunized mice was evaluated against viral antigens of the HCV structural region. As shown in Figure 24, there was a variation in the stimulation rates when The spleen cells of mice immunized with the conjugate combination (MenC-P64k) -VHC vaccine preparation were stimulated with the antigens of the structural region of HCV compared to the control group of mice immunized only with the vaccine vaccine against HCV. Another negative control group (Group 4), corresponding to non-immunized mice, was included in this experiment.
- FIG. 25 shows the results obtained, where there was no difference in the viral titer determined in the ovaries of the mice immunized with the vaccine vaccine against HCV with or without the conjugate (MenC-P64k) and subsequently challenged with the recombinant vaccinia virus .
- results shown in Table 4 indicate that the mixture of the vaccine preparation against HCV with and the MenC-P64K conjugate had no influence on the generation of specific-functional antibodies against the N. meningitidis bacteria, generated at from the MenC-P64K conjugate itself.
- Bactericidal titres are expressed as Log 2 of the last dilution of the serum capable of killing 50% of the initial inoculum of bacteria used in the assay.
- Example 9 Evaluation of the immune response in BALB / c mice after immunization with HCV protein preparations mixed with plasmids encoding viral antigens.
- mice were immunized with: group 1- pAEC-M7, group 2- pAEC-M7-vaccine prepared against HCV, group 3- pAEC-M7-HBsAg, group 4- pAEC-M7-H BsAg- vaccine prepared against HCV, group 5- pAEC-M7-HBcAg, group 6- pAEC-M7- HBcAg-vaccine prepared against HCV, group 7- vaccine prepared against HCV.
- the immunization scheme used was 0, 2, 4, 6 weeks, by im route.
- the antibody response was evaluated against the 3 antigens that make up the structural region of HCV (capsid antigen, E1 and E2 of HCV), as well as against the surface antigens (HBsAg) and the capsid (HBcAg) of the Hepatitis B virus.
- the results obtained are shown in Figure 26, where the generation of specific response for each of the evaluated antigens is observed.
- Higher antibody titres against HCV structural proteins are generally appreciated when plasmids were mixed with the HCV vaccine preparation compared to the vaccine preparation alone. Although this was the trend, the differences observed were not statistically significant. Both against HBsAg and HBcAg, the antibody levels detected were similar, when immunized with plasmids coding for these antigens, alone or in admixture with the vaccine against HCV.
- the lymphoproliferative response in the spleen cells of the immunized mice was evaluated against viral antigens of the structural region of HCV, as well as against HBsAg and HBcAg, 15 days after the end of the immunization schedule. As shown in Figure 27, there was no statistically significant variation in the stimulation indices when the mixed vaccine preparation was compared with the plasmids encoding viral antigens (HBsAg or HBcAg) and their respective controls. Another negative control group (Group 8), corresponding to non-immunized mice, was included in this experiment. An antigen-specific response was generated in each case. The differences in the stimulation indexes detected were not statistically significant, when the study groups were compared. Nor was there a statistically significant difference between the groups of mice immunized with the vaccine preparation, in the presence or absence of plasmids, when spleen cells were pulsed in the presence of the HCV structural region antigens.
- Example 10 Evaluation of the immune response in BALB / c mice after immunization with DNA preparations coding for antigens of the structural region of HCV and dose boosters with the HCV protein preparations under study.
- the combination of the immunization with DNA with booster dose using the vaccine preparation against HCV was studied in BALB / c mice.
- the immunization scheme is the one shown in Table 5.
- mice were immunized with the preparation of plasmid DNA (Due ⁇ as-Carrera, et al. (2002) Enhancement of the immune response generated against the hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol Appl Biochem, 35 , 205-212) by im route and subsequently the booster dose was administered by ip route.
- the antibody response was evaluated against the 3 antigens that make up the structural region of HCV (capsid antigen, E1 and E2 of HCV). The results obtained are shown in Figure 29. No potentiation of the antibody response against the HCV capsid antigen was evidenced.
- Antibody levels detected were higher for protein variants compared to groups immunized with DNA, although the differences were not statistically significant.
- the antibody response against E1 was enhanced by administering the booster dose with the vaccine preparation. In this case, the highest levels of antibodies were detected in the groups of animals immunized with protein compared to those immunized with DNA. The differences observed in the levels of antibodies against E1, after the booster dose, had no statistical significance.
- the levels of antibodies detected in this immunization regime against E2 showed higher levels of antibodies for animals immunized with protein variants compared to the response obtained in animals immunized with DNA. After the booster dose, the antibody levels were not modified.
- lymphoproliferative response in the spleen cells of the immunized mice was evaluated against the viral antigens of the HCV structural region, 15 days after the end of the immunization schedule. As shown in Figure 30, although there was an increase in lymphoproliferation rates in the case of protein variants with reinforcement, the differences were not statistically significant. Similarly, in the case of mice immunized with DNA and with booster doses with protein, there was an increase in the lymphoproliferative response for all cases against all antigens and marked mainly against the protein. The differences observed were not statistically significant.
- Example 11 Evaluation of the immune response in BALB / c mice after immunization with HCV protein preparations taking into account different forms of preparation.
- the generation of the immune response against the recombinant proteins of the structural region of HCV 1 were studied after the preparation of the immunogen of different ways. The following variants were studied: (1) The three antigens were mixed and subsequently adjuvated with the aluminum hydroxide gel, (2) Each antigen separately was adjuvated with the aluminum hydroxide gel and subsequently mixed to form the final preparation. BALB / c mice were immunized with both preparations. The optimal vaccine preparation was used for the generation of a cellular response in BALB / c mice. The immunization scheme used was 0, 2, 4 weeks and the immune response was studied 15 days after the end of the immunization scheme.
- the antibody response was evaluated against the 3 antigens that form the vaccine preparation (capsid antigen, E1 and E2 of HCV).
- Figure 32 shows that the levels of antibodies generated for each antigen under analysis were similar, with no statistically significant differences between those studied.
- the lymphoproliferative response in the spleen cells of the immunized mice was evaluated against viral antigens of the HCV structural region.
- the immunogen preparation form had no influence on the specific antigen lymphoproliferative response obtained. No statistically significant differences were detected between the groups under study.
- Another negative control group (Group 3), corresponding to non-immunized mice, was included in this experiment.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2007002659A MX2007002659A (es) | 2004-09-03 | 2005-08-29 | Composicion vacunal contra el virus de la hepatitis c. |
AU2005279590A AU2005279590B2 (en) | 2004-09-03 | 2005-08-29 | Vaccine composition against hepatitis C virus |
EP20050779477 EP1785143B1 (en) | 2004-09-03 | 2005-08-29 | Vaccine composition against hepatitis c virus |
KR1020077006792A KR101245154B1 (ko) | 2004-09-03 | 2005-08-29 | 간염 c 바이러스에 대한 백신 조성물 |
CN2005800362181A CN101043902B (zh) | 2004-09-03 | 2005-08-29 | 针对丙型肝炎病毒的疫苗组合物 |
CA 2577918 CA2577918C (en) | 2004-09-03 | 2005-08-29 | Vaccine composition against hepatitis c virus |
BRPI0514884-7A BRPI0514884A (pt) | 2004-09-03 | 2005-08-29 | composição vacinal para gerar resposta imune celular e humoral protetora contra a infecção pelo vìrus de hepatite c |
JP2007528569A JP4917539B2 (ja) | 2004-09-03 | 2005-08-29 | C型肝炎ウイルスに対するワクチン組成物 |
US11/661,217 US20080138360A1 (en) | 2004-09-03 | 2005-08-29 | Vaccine Composition Against Hepatitis C Virus |
HK07114321A HK1109069A1 (en) | 2004-09-03 | 2007-12-31 | Vaccine composition against hepatitis c virus |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CU2004-0189 | 2004-09-03 | ||
CU20040189A CU23496A1 (es) | 2004-09-03 | 2004-09-03 | Composición vacunal contra el virus de la hepatitis c |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006024240A2 true WO2006024240A2 (es) | 2006-03-09 |
WO2006024240A3 WO2006024240A3 (es) | 2006-06-01 |
Family
ID=40262832
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CU2005/000005 WO2006024240A2 (es) | 2004-09-03 | 2005-08-29 | Composición vacunal contra el virus de la hepatitis c. |
Country Status (15)
Country | Link |
---|---|
US (1) | US20080138360A1 (es) |
EP (1) | EP1785143B1 (es) |
JP (1) | JP4917539B2 (es) |
KR (1) | KR101245154B1 (es) |
CN (1) | CN101043902B (es) |
AR (1) | AR052639A1 (es) |
AU (1) | AU2005279590B2 (es) |
BR (1) | BRPI0514884A (es) |
CA (1) | CA2577918C (es) |
CU (1) | CU23496A1 (es) |
HK (1) | HK1109069A1 (es) |
MX (1) | MX2007002659A (es) |
RU (1) | RU2351363C2 (es) |
WO (1) | WO2006024240A2 (es) |
ZA (1) | ZA200701674B (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2066354T3 (da) | 2006-09-29 | 2013-05-27 | Ligocyte Pharmaceuticals Inc | Norovirus vaccine formuleringer |
JP2010539192A (ja) | 2007-09-18 | 2010-12-16 | リゴサイト ファーマスーティカルズ,インコーポレイテッド | ノロウイルスに対して防御免疫応答を付与する方法 |
US20100266636A1 (en) | 2007-09-18 | 2010-10-21 | Ligocyte Pharmaceuticals, Inc. | Method of conferring a protective immune response to norovirus |
CN104911154A (zh) * | 2008-08-08 | 2015-09-16 | 武田疫苗股份有限公司 | 交叉反应性增强的包含复合衣壳氨基酸序列的病毒样颗粒 |
JP6208659B2 (ja) | 2011-07-11 | 2017-10-04 | タケダ ワクチン,インコーポレイテッド | 非経口ノロウイルスワクチン製剤 |
RU2510998C2 (ru) * | 2012-08-01 | 2014-04-10 | Николай Николаевич Грановский | ВАКЦИНА НА ОСНОВЕ ВИРУСОПОДОБНЫХ ЧАСТИЦ, СОДЕРЖАЩИХ ВСЕ СТРУКТУРНЫЕ АНТИГЕНЫ ВИРУСА ГЕПАТИТА С, И СПОСОБ ЕЕ ПОЛУЧЕНИЯ В ДРОЖЖАХ Hansenula polymorpha |
CU24112B1 (es) * | 2012-11-05 | 2015-08-27 | Ct De Ingeniería Genética Y Biotecnología | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7070790B1 (en) * | 1993-06-29 | 2006-07-04 | The United States Of America As Represented By The Department Of Health And Human Services | Nucleotide and deduced amino acid sequences of the envelope 1 and core genes of isolates of hepatitis C virus and the use of reagents derived from these sequences in diagnostic methods and vaccines |
ATE269064T1 (de) * | 1994-10-05 | 2004-07-15 | Apollon Inc | Impfstoffe gegen den hepatitis b und c virus |
WO1998021338A1 (en) * | 1996-11-08 | 1998-05-22 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Synthesis and purification of hepatitis c virus-like particles |
CA2391843C (en) * | 1999-11-19 | 2011-10-18 | Csl Limited | Hcv vaccine compositions |
AU2002225895A1 (en) * | 2000-11-07 | 2002-05-21 | Anadys Pharmaceuticals, Inc. | Hepatitis c virus constructs characterized by high efficiency replication |
US7101561B2 (en) * | 2000-12-01 | 2006-09-05 | Innogenetics N.V. | Purified hepatitis C virus envelope proteins for diagnostic and therapeutic use |
US20030021805A1 (en) * | 2001-05-29 | 2003-01-30 | Barber Glen N. | Generation of HCV-like particles and chimeric HCV virus |
CU23244A1 (es) * | 2001-07-16 | 2007-10-17 | Ct Ingenieria Genetica Biotech | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
DE10143490C2 (de) * | 2001-09-05 | 2003-12-11 | Gsf Forschungszentrum Umwelt | Rekombinantes MVA mit der Fähigkeit zur Expression von HCV Struktur-Antigenen |
-
2004
- 2004-09-03 CU CU20040189A patent/CU23496A1/es not_active IP Right Cessation
-
2005
- 2005-08-22 AR ARP050103513 patent/AR052639A1/es not_active Application Discontinuation
- 2005-08-29 EP EP20050779477 patent/EP1785143B1/en active Active
- 2005-08-29 BR BRPI0514884-7A patent/BRPI0514884A/pt not_active IP Right Cessation
- 2005-08-29 JP JP2007528569A patent/JP4917539B2/ja not_active Expired - Fee Related
- 2005-08-29 AU AU2005279590A patent/AU2005279590B2/en not_active Ceased
- 2005-08-29 CA CA 2577918 patent/CA2577918C/en not_active Expired - Fee Related
- 2005-08-29 KR KR1020077006792A patent/KR101245154B1/ko not_active IP Right Cessation
- 2005-08-29 US US11/661,217 patent/US20080138360A1/en not_active Abandoned
- 2005-08-29 CN CN2005800362181A patent/CN101043902B/zh not_active Expired - Fee Related
- 2005-08-29 WO PCT/CU2005/000005 patent/WO2006024240A2/es active Application Filing
- 2005-08-29 MX MX2007002659A patent/MX2007002659A/es active IP Right Grant
- 2005-08-29 RU RU2007112117A patent/RU2351363C2/ru not_active IP Right Cessation
-
2007
- 2007-02-26 ZA ZA200701674A patent/ZA200701674B/xx unknown
- 2007-12-31 HK HK07114321A patent/HK1109069A1/xx not_active IP Right Cessation
Non-Patent Citations (1)
Title |
---|
None |
Also Published As
Publication number | Publication date |
---|---|
JP2008511556A (ja) | 2008-04-17 |
CA2577918C (en) | 2013-05-28 |
EP1785143A2 (en) | 2007-05-16 |
KR101245154B1 (ko) | 2013-03-19 |
BRPI0514884A (pt) | 2008-06-24 |
ZA200701674B (en) | 2008-08-27 |
AU2005279590B2 (en) | 2010-12-16 |
EP1785143B1 (en) | 2015-03-04 |
CN101043902A (zh) | 2007-09-26 |
AR052639A1 (es) | 2007-03-28 |
US20080138360A1 (en) | 2008-06-12 |
AU2005279590A1 (en) | 2006-03-09 |
WO2006024240A3 (es) | 2006-06-01 |
HK1109069A1 (en) | 2008-05-30 |
CN101043902B (zh) | 2012-04-18 |
MX2007002659A (es) | 2007-05-16 |
JP4917539B2 (ja) | 2012-04-18 |
KR20070057861A (ko) | 2007-06-07 |
RU2007112117A (ru) | 2008-10-10 |
RU2351363C2 (ru) | 2009-04-10 |
CU23496A1 (es) | 2010-02-23 |
CA2577918A1 (en) | 2006-03-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BenMohamed et al. | Lipopeptide vaccines—yesterday, today, and tomorrow | |
US20100047271A1 (en) | Vaccine compositions | |
EP2391383B1 (en) | Codon-optimized hepatitis b virus core antigen (hbcag) | |
AU2005279590B2 (en) | Vaccine composition against hepatitis C virus | |
JP6259831B2 (ja) | C型肝炎ウイルスに対するキメラワクチン抗原 | |
US8691234B2 (en) | Vaccine formulation potentiated by the combination of DNA and an antigen | |
Howard | New vaccine technologies and the control of viral hepatitis | |
Lobaina et al. | Caracterización de la respuesta immune generada por administración intramuscular de los antígenos de superficie y nucleocápsida del virus de la Hepatitis B |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2577918 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007528569 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/002659 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005779477 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2299/DELNP/2007 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077006792 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005279590 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007112117 Country of ref document: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580036218.1 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 2005279590 Country of ref document: AU Date of ref document: 20050829 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005279590 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2005779477 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11661217 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0514884 Country of ref document: BR |